Mendillo Jane L

SEC Form 4 insider trading activity

Mendillo Jane L has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Mar 2, 2026.

On the most recent filing, Mendillo Jane L is listed as Director at Generate Biomedicines, Inc. Inside the rolling window, Mendillo Jane L reported 1 open-market purchase totaling $24K in GENB and no open-market sales.

Companies traded

Other insiders at GENB

Insider Buying

$24K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
GENB
Mendillo Jane L
Purchase$24KMar 2SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Mendillo Jane L made?

Mendillo Jane L has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.

Which companies does Mendillo Jane L trade?

Mendillo Jane L has filed SEC Form 4 disclosures for 1 company, including GENB.

When was Mendillo Jane L's most recent SEC Form 4 filing?

Mendillo Jane L's most recent SEC Form 4 filing on Tracefour is dated Mar 2, 2026.

What is Mendillo Jane L's total buy and sell value in the current window?

Inside the rolling retention window, Mendillo Jane L bought $24K and sold $0 based on SEC Form 4 filings.

What was Mendillo Jane L's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 1,500 GENB shares on 2026-03-02, worth $24K, per SEC Form 4 filings.